Skip to main content

Table 3 Demographic and clinical characteristics of patients who received EGFR-TKI

From: EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors

 Overall
[A]
Patients who received 1 L EGFR-TKI
[B]
Patients who received 2 L+ EGFR-TKI
[C]
P-value for
[B] vs [C]
(N = 782)(N = 435)(N = 347)
Observation period, days, mean ± SD [median]371.5 ± 312.3 [309.0]435.5 ± 329.7 [372.0]291.3 ± 268.7 [220.0]< 0.001
Age at metastatic NSCLC diagnosis, years, mean ± SD [median]67.9 ± 10.2 [69.0]69.4 ± 10.5 [70.0]66.1 ± 9.5 [66.0]< 0.001
Female, n (%)497 (63.6)315 (72.4)182 (52.4)< 0.001
Race, n (%)
 White440 (56.3)246 (56.6)194 (55.9)0.857
 Asian68 (8.7)43 (9.9)25 (7.2)0.186
 Black73 (9.3)40 (9.2)33 (9.5)0.881
 Other111 (14.2)56 (12.9)55 (15.9)0.236
 Unknown90 (11.5)50 (11.5)40 (11.5)0.988
Geographic region, n (%)
 Northeast142 (18.2)81 (18.6)61 (17.6)0.707
 West132 (16.9)76 (17.5)56 (16.1)0.621
 Midwest111 (14.2)51 (11.7)60 (17.3)0.027
 South284 (36.3)145 (33.3)139 (40.1)0.052
 Unknown107 (13.7)79 (18.2)28 (8.1)< 0.001
Community-based practice, n (%)681 (87.1)359 (82.5)322 (92.8)< 0.001
Insurance type, n (%)a,b
 Commercial Health Plan379 (48.5)198 (45.5)181 (52.2)0.065
 Medicare300 (38.4)169 (38.9)131 (37.8)0.754
 Other payer246 (31.5)127 (29.2)119 (34.3)0.127
 Patient assistance program60 (7.7)11 (2.5)49 (14.1)< 0.001
 Medicaid47 (6.0)17 (3.9)30 (8.6)0.006
 Other government program31 (4.0)11 (2.5)20 (5.8)0.021
 Self pay7 (0.9)4 (0.9)3 (0.9)0.935
 Unknown115 (14.7)73 (16.8)42 (12.1)0.066
History of smoking, n (%)
 History of smoking493 (63.0)234 (53.8)259 (74.6)< 0.001
 No history of smoking287 (36.7)199 (45.7)88 (25.4)< 0.001
 Unknown2 (0.3)2 (0.5)0 (0.0)0.206
Histology at NSCLC diagnosis, n (%)
 Non-squamous cell carcinoma655 (83.8)402 (92.4)253 (72.9)< 0.001
 Squamous cell carcinoma98 (12.5)19 (4.4)79 (22.8)< 0.001
 NSCLC histology - not otherwise specified29 (3.7)14 (3.2)15 (4.3)0.417
Time from metastatic NSCLC diagnosis to index date, days, Q1 | Median | Q3
 Overall44 | 202 | 47822 | 62 | 336177 | 328 | 553< 0.001
 Stage I-IIIA29 | 158 | 50517 | 50 | 312171 | 372 | 589< 0.001
 Stage IIIB-IV72 | 221 | 47225 | 90 | 337182 | 319 | 552< 0.001
ECOG assessment during the baseline period (including index date), n (%)413 (52.8)212 (48.7)201 (57.9)0.011
ECOG performance status nearest or on the index date
 0126 (30.5)79 (37.3)47 (23.4)0.002
 1189 (45.8)84 (39.6)105 (52.2)0.010
 282 (19.9)40 (18.9)42 (20.9)0.606
 316 (3.9)9 (4.2)7 (3.5)0.688
 40 (0.0)0 (0.0)0 (0.0)
EGFR testing between the date of NSCLC diagnosis and the index date, n (%)
 Tested555 (71.0)292 (67.1)263 (75.8)0.008
 Positive355 (64.0)242 (82.9)113 (43.0)< 0.001
 T790M mutation5 (1.4)3 (1.2)2 (1.8)0.693
 Exon 19 deletion141 (39.7)100 (41.3)41 (36.3)0.366
 L858R point mutation in exon 21134 (37.7)104 (43.0)30 (26.5)0.003
 Double mutation9 (2.5)5 (2.1)4 (3.5)0.411
 Other mutation type48 (13.5)19 (7.9)29 (25.7)< 0.001
 Unknown18 (5.1)11 (4.5)7 (6.2)0.509
 Negative175 (31.5)42 (14.4)133 (50.6)< 0.001
 Results pending2 (0.4)0 (0.0)2 (0.8)0.135
 Unsuccessful/indeterminate test23 (4.1)8 (2.7)15 (5.7)0.080
Sample type among those tested
 Tissue482 (86.8)263 (90.1)219 (83.3)0.018
 Blood60 (10.8)20 (6.8)40 (15.2)0.002
 Unknown14 (2.5)10 (3.4)4 (1.5)0.153
  1. 1 L first line, 2 L+ second or later line, ECOG European Oncology Cooperative Group, EGFR epidermal growth factor receptor, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor, NSCLC non-small cell lung cancer, Q1 first quartile, Q3 third quartile; SD: standard deviation
  2. a Evaluated on the index date
  3. b Patients may have primary and secondary insurance (i.e. patients may have more than one type of insurance). Unknown insurance type was defined as patients without any types of insurance